Name: Anti-Human PD1 (Spartalizumab Biosimilar)
Brand: InnoCyto
SKU: 505801
Price: 220 USD
Availability: InStock

Shop Now Contact

Anti-Human PD1 (Spartalizumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
505801	1 mg	$220
505802	5 mg	$650
505803	20 mg	$2000

Bulk/Custom

Product Details

Clone	Spartalizumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human PD-1 (Spartalizumab Biosimilar)
Isotype	Human IgG4
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human PD1
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	CD279
RRID	AB_3739333
Target Name	PD1, PD-1, PDCD1, CD279, SLEB2
Antibody Type	Recombinant
Research Areas	Immune Checkpoints, Activated T cells, Cancer Immunology, Tregs, Tfh cells, Activated B cells
See All Formats	Clone Spartalizumab

Background Information

Spartalizumab is a fully human monoclonal antibody of the immunoglobulin G4 kappa (IgG4κ) subclass, specifically engineered to bind to and inhibit the programmed death-1 (PD-1) receptor, an immune checkpoint expressed on activated T lymphocytes. Structurally, Spartalizumab is a glycoprotein with a molecular weight of approximately 147 kilodaltons (kDa). It consists of two identical heavy chains and two identical light chains linked by interchain disulfide bonds, forming the typical Y-shaped architecture found in IgG antibodies. Each heavy chain comprises a variable (VH) domain and three constant domains (CH1-CH3), while each light chain contains one variable (VL) and one constant (CL) domain. It is expressed in mammalian cell systems, commonly Chinese Hamster Ovary (CHO) cells, to ensure proper glycosylation, folding, and structural integrity.

The variable domains contain complementarity-determining regions (CDRs) that form the antigen-binding sites responsible for high-affinity and specific interaction with PD-1’s extracellular domain. The CDRs engage PD-1 through a combination of hydrogen bonding, electrostatic interactions, and hydrophobic contacts, blocking its binding to endogenous ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). This blockade disrupts the inhibitory signaling cascade mediated by PD-1 engagement, which normally suppresses T-cell activation. In immunological model systems, Spartalizumab prevents the attenuation of T-cell receptor (TCR) signaling, contributing to sustained cytokine production, proliferation, and effector activity.

The Fc (fragment crystallizable) region of Spartalizumab is derived from the IgG4 subclass, which is selected for its naturally low capability to elicit immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To enhance structural stability, the hinge region contains an S228P mutation that prevents half-antibody exchange. The Fc domain also interacts with neonatal Fc receptors (FcRn), enabling antibody recycling and prolonging plasma half-life.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips